Greenleaf Trust Has $1.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenleaf Trust lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,909 shares of the biopharmaceutical company’s stock after selling 42 shares during the period. Greenleaf Trust’s holdings in Regeneron Pharmaceuticals were worth $1,360,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of REGN. Centaurus Financial Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $118,000. Czech National Bank increased its position in shares of Regeneron Pharmaceuticals by 7.0% during the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after acquiring an additional 1,405 shares in the last quarter. Park Avenue Securities LLC increased its position in shares of Regeneron Pharmaceuticals by 7.6% during the third quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock worth $1,986,000 after acquiring an additional 134 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 32.6% during the third quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock worth $1,510,000 after acquiring an additional 353 shares in the last quarter. Finally, Miracle Mile Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 12.6% during the third quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $2,693,000 after acquiring an additional 286 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Stock Down 0.9 %

Regeneron Pharmaceuticals stock opened at $666.85 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $73.28 billion, a price-to-earnings ratio of 16.50, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $663.43 and a fifty-two week high of $1,211.20. The stock’s fifty day moving average is $720.81 and its two-hundred day moving average is $921.72.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.